Latest Commercialisation News

CurveBeam AI has inked a decade-long exclusive partnership with a major Chinese medical device joint venture, unlocking rapid market entry and a $10 million capital boost to expand its weight bearing CT and AI solutions across Greater China.

SomnoMed reports a strong start to FY26 with 13.5% revenue growth and confirms the Clayton Sleep Institute as the first US site for its pivotal Rest Assure clinical study, backed by FDA protocol agreement.

Hiremii Limited reported a 6% revenue increase and an 18% rise in gross profit for Q1 FY26, driven by global job board integration and a successful capital raise to fuel its AI-powered recruitment platform.

Unith Ltd reports a 32% rise in Q1 FY26 cash receipts and unveils its breakthrough Streaming Avatars technology, alongside a successful $1.85 million capital raise.

Sprintex Limited has transitioned from development to commercial execution, securing major contracts in Europe, China, and India while raising A$1.5m to fund expansion.

Green Critical Minerals advances its Very High Density graphite technology with strong thermal performance validation, production scale-up, and strategic moves into global markets including a planned US listing.

Scorpion Minerals reports promising shallow gold intercepts at its Pharos Project and announces a strategic collaboration with Gylden Resources, enhancing processing options in Western Australia’s Murchison region.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

1414 Degrees has completed key milestones on its SiBox technology, advanced SiBrick storage media towards mass production, and acquired an exclusive licence for innovative silicon nanoparticle tech, backed by a $1.214 million capital raise.

Archer Materials has successfully demonstrated that its blood potassium Biochip can be fabricated on a silicon platform, matching clinical accuracy standards and accelerating its path to commercialisation.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.